BHVN vs. VTRS, UTHR, RDY, SRPT, CTLT, ROIV, ELAN, LEGN, CERE, and ASND
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
Biohaven has a net margin of 0.00% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Biohaven's return on equity.
Biohaven presently has a consensus price target of $51.63, indicating a potential upside of 47.08%. Viatris has a consensus price target of $11.00, indicating a potential upside of 3.77%. Given Biohaven's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biohaven is more favorable than Viatris.
Biohaven received 352 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 65.55% of users gave Biohaven an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Viatris has higher revenue and earnings than Biohaven. Viatris is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biohaven had 13 more articles in the media than Viatris. MarketBeat recorded 18 mentions for Biohaven and 5 mentions for Viatris. Biohaven's average media sentiment score of 0.66 beat Viatris' score of -0.07 indicating that Biohaven is being referred to more favorably in the media.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Biohaven beats Viatris on 13 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
